Literature DB >> 35195765

Utility of gadolinium for identifying the malignant potential of pancreatic cystic lesions.

Andrea S Kierans1, Alexander Gavlin2, Natasha Wehrli2, Laura M Flisnik3, Sarah Eliades4, Meredith E Pittman5.   

Abstract

PURPOSE: To determine if gadolinium is necessary for the diagnosis of a pancreatic cystic lesion (PCL) as benign or malignant by assessing inter- and intra-observer agreement and diagnostic accuracy for the presence of worrisome features/high-risk stigmata on non-contrast MRI compared to MRI with and without contrast, with cytopathology as a reference standard.
METHODS: The institutional database was searched to identify consecutive patients that underwent EUS/FNA or surgical resection of an asymptomatic PCL performed from 01/01/2015 to 01/01/2019. Two abdominal radiologists independently evaluated PCLs on MRI with all sequences except for contrast-enhanced sequences followed by a second reading with data from the entire MRI including pre- and post-contrast sequences. Cyst size, growth, and the presence of worrisome features/high-risk stigmata were assessed for each cyst on both datasets.
RESULTS: There were 87 patients with 87 pancreatic cysts; 76(87.4%) were benign and 11 (12.7%) were malignant. The presence of any worrisome features/high-risk stigmata for reader 1 was concordant on both MRIs in 95.4% (83/87; k = 0.874) of cases and for reader 2 was concordant in 96.6% (84/87; k = 0.920) of cases. The diagnostic accuracy of the two datasets when the presence of any worrisome feature/high-risk stigmata was predictive of malignancy was identical for reader 1 (AUC = 0.622 for both; p = 1.0) and similar for reader 2 (AUC 0.569 and 0.589; p = 0.08) for both MRI datasets.
CONCLUSION: The addition of gadolinium had no significant impact in the diagnosis of a benign versus malignant PCL, with similar intra-observer agreement and diagnostic accuracy for both readers when using contrast-enhanced and unenhanced MRI datasets.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Gadolinium; IPMN; MRI; Pancreatic cystic lesion

Mesh:

Substances:

Year:  2022        PMID: 35195765     DOI: 10.1007/s00261-022-03446-z

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  24 in total

Review 1.  Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas.

Authors:  Masao Tanaka; Carlos Fernández-Del Castillo; Terumi Kamisawa; Jin Young Jang; Philippe Levy; Takao Ohtsuka; Roberto Salvia; Yasuhiro Shimizu; Minoru Tada; Christopher L Wolfgang
Journal:  Pancreatology       Date:  2017-07-13       Impact factor: 3.996

2.  High prevalence of pancreatic cysts detected by screening magnetic resonance imaging examinations.

Authors:  Koen de Jong; C Yung Nio; John J Hermans; Marcel G Dijkgraaf; Dirk J Gouma; Casper H J van Eijck; Eddy van Heel; Gunter Klass; Paul Fockens; Marco J Bruno
Journal:  Clin Gastroenterol Hepatol       Date:  2010-06-01       Impact factor: 11.382

3.  Management of Incidental Pancreatic Cysts: A White Paper of the ACR Incidental Findings Committee.

Authors:  Alec J Megibow; Mark E Baker; Desiree E Morgan; Ihab R Kamel; Dushyant V Sahani; Elliot Newman; William R Brugge; Lincoln L Berland; Pari V Pandharipande
Journal:  J Am Coll Radiol       Date:  2017-05-19       Impact factor: 5.532

4.  Incidental pancreatic cystic lesions: is there a relationship with the development of pancreatic adenocarcinoma and all-cause mortality?

Authors:  Victoria Chernyak; Milana Flusberg; Linda B Haramati; Alla M Rozenblit; Eran Bellin
Journal:  Radiology       Date:  2014-08-12       Impact factor: 11.105

5.  Association Between Advances in High-Resolution Cross-Section Imaging Technologies and Increase in Prevalence of Pancreatic Cysts From 2005 to 2014.

Authors:  Maria Moris; Mellena D Bridges; Robert A Pooley; Massimo Raimondo; Timothy A Woodward; John A Stauffer; Horacio J Asbun; Michael B Wallace
Journal:  Clin Gastroenterol Hepatol       Date:  2015-09-11       Impact factor: 11.382

6.  Pancreatic cyst prevalence and the risk of mucin-producing adenocarcinoma in US adults.

Authors:  Timothy B Gardner; Lisa M Glass; Kerrington D Smith; Gregory H Ripple; Richard J Barth; David A Klibansky; Thomas A Colacchio; Michael J Tsapakos; Arief A Suriawinata; Gregory J Tsongalis; J Marc Pipas; Stuart R Gordon
Journal:  Am J Gastroenterol       Date:  2013-10       Impact factor: 10.864

7.  Is gadolinium necessary for MRI follow-up evaluation of cystic lesions in the pancreas? Preliminary results.

Authors:  Michael Macari; Terrence Lee; Sooah Kim; Stacy Jacobs; Alec J Megibow; Cristina Hajdu; James Babb
Journal:  AJR Am J Roentgenol       Date:  2009-01       Impact factor: 3.959

8.  Cystic neoplasms of the pancreas and tumor-like lesions with cystic features: a review of 418 cases and a classification proposal.

Authors:  M Kosmahl; U Pauser; K Peters; B Sipos; J Lüttges; B Kremer; G Klöppel
Journal:  Virchows Arch       Date:  2004-06-08       Impact factor: 4.064

9.  Difference analysis in prevalence of incidental pancreatic cystic lesions between computed tomography and magnetic resonance imaging.

Authors:  Shuo Zhu; Wen-Tao Wang; Xiao-Sha Shang; Ting Ni; Wen-Chuan Wu; Wen-Hui Lou; Meng-Su Zeng; Sheng-Xiang Rao
Journal:  BMC Med Imaging       Date:  2019-05-24       Impact factor: 1.930

Review 10.  Overview and comparison of guidelines for management of pancreatic cystic neoplasms.

Authors:  Aws Hasan; Kavel Visrodia; James J Farrell; Tamas A Gonda
Journal:  World J Gastroenterol       Date:  2019-08-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.